Practical insights into assay design, kinetics, and structural validation
Autors:
Johan Veerman, Payman Sadek, Pim de Vink, Masa Kobayashi and Gregg Siegal
ZoBio B.V., Oncodesign Services
Abstract :
For over a century, covalent medicines have contributed to the treatment of human disease. Historically, their design was approached with caution due to concerns about toxicity and off-target effects. Today, however, covalent drugs are back in the spotlight, with recent successes demonstrating their potential for both power and precision.
Advances in screening technologies are creating new opportunities to discover and optimize covalent binders, yet the path remains challenging. Drawing on our experience, we have prepared an overview of the key challenges, along with practical solutions and strategies for effective covalent screening. Explore our recent poster to learn how can we find new, progressible hits by screening covalent compound libraries.